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Background: Although primary cancer of the fallopian tubes is a relatively rare type of tumor in fe-
male reproductive organs, its mortality is quite high. It is important to identify molecular and bio-
logical markers of this malignancy that determine its specific phenotype. Methods: The study was 
carried out on samples received from 71 female patients with primary cancer of the fallopian 
tubes. The main molecular and biological properties, including hormone status (estrogen receptor 
[ER], progesterone receptor [PR]), human epidermal growth factor receptor (HER2)/neu expression, 
proliferative potential (Ki-67), apoptosis (p53, Bcl-2), and pro-angiogenic (vascular endothelial 
growth factor) quality of serous tumors were studied in comparison with clinical and morphological 
characteristics. Results: ER and PR expression is accompanied by low grade neoplasia, early clini-
cal disease stage, and absence of lymphogenic metastasis (p < .001). HER2/neu expression is not 
typical for primary cancer of the fallopian tubes. Ki-67 expression is characterized by an inverse 
correlation with ER and PR (p < .05) and is associated with lymphogenic metastasis (p < .01). p53+ 
status correlates with high grade malignancy, tumor progression, metastasis, negative ER/PR (p < 
.001), and negative Bcl-2 status (p < .05). Positive Bcl-2 status is positively correlated with ER and 
PR expression and low grade malignancy. Conclusions: Complex morphologic (histological and 
immunohistochemical) study of postoperative material allows estimation of the degree of malig-
nancy and tumor spread to enable appropriate treatment for each case.
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▒ ORIGINAL ARTICLE ▒
Primary cancer of the fallopian tubes (PCFT) has the lowest 
incidence of tumors of the female reproductive organs, but its 
mortality is quite high.1 It was first described in a small number 
of patients as sporadic observations. The cause, frequency, diagno-
sis, prevention, and treatment of PCFT are insufficiently illumi-
nated in the modern medical literature. The incidence of malig-
nant tumors of the fallopian tubes (FT) ranges from 0.14% to 
1.8% among all malignant tumors of the female reproductive 
system.2-5 While it is difficult to identify the initial tumor process 
of tubo-ovarian tumors, FT malignant tumors are often regarded 
as a type of ovarian cancer. Consequently, these tumors are much 
more frequent in gynecologic practice.6,7 This causes signifi-
cant discrepancies regarding reports of PCFT morbidity, which 
undoubtedly depends on the quality of morphologic diagnosis. 
Practically, FT carcinomas are found more frequently in onco-
gynecology. Moreover, they serve as the primary source for serous 
and mucinous tumors of the ovaries and peritoneum.8-11 In-
creased oncologic awareness and improved diagnostic methods 
have led to a relative increase in the PCFT detection rate in recent 
years.12 The main prognostically important criteria remain tumor 
clinical stage and their degree of malignancy.13,14 The rarity of 
PCFT has made it impossible to identify significant predictive 
factors thus far. Identification of tumor markers in PCFT tissue 
may provide important diagnostic and prognostic information 
about the biological properties of this neoplasm.
Information about tumor hormonal status (estrogen receptor 
[ER] and progesterone receptor [PR]), proliferative potential 
(Ki-67), anti-apoptotic properties (p53 and Bcl-2), and ability 
to stimulate angiogenesis (vascular endothelial growth factor 
[VEGF]) will undoubtedly serve as the basis for a pathophysio-
logic understanding of the molecular properties of FT cancer. 
Further information may allow identification of new target ther-
apeutic methods for PCFT. Investigation of these tumor param-
eters is the aim of this study.
MATERIALS AND METHODS
The material was collected from Sumy Regional Pathology 
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Clinical Center and Sumy Regional Clinical Oncology Center. 
Written informed consent to investigate tissue was obtained 
from patients. The Bioethics Commission of the Medical Insti-
tute of Sumy State University approved the experimental protocol 
(No. 8 from 29.04.2016).
The research was performed on surgical material obtained 
from 71 female patients with PCFT. Pathologic findings were 
identified using SEE-FIM protocols of FT tissue examination. 
Determination of the primacy of FT lesions was based on the 
following criteria: main tumor focus localized in the FT with 
spread from the endosalpinx for ovary and/or uterus involve-
ment; FT contained more neoplastic mass tissue than other sites; 
border between normal and affected (neoplastic) epithelium of 
the tube was visualized; no malignant neoplasms of other local-
izations. 
Hematoxylin-eosin stained tissue sections of 5-μm thickness 
allowed determination of the histogenesis, degree of tumor ma-
lignancy, depth of invasion, spread into pelvic organs, and pres-
ence of metastases in regional lymph nodes.
For immunohistochemical study, 4-μm sections were made 
from paraffin blocks, subjected to standard deparaffinization, 
dehydrated in xylene and ethanol of graded concentrations, and 
mounted on 3-aminopropyltriethoxysilane-coated slides. Anti-
gen retrieval was carried out in a water-bath at 97°C–98°C. 
Antigen-antibody reaction was visualized using the Ultra Vision 
Quanto Detection System HRP DAB Chromogen (Thermo 
Fisher Scientific, Waltham, MA, USA), which included block-
ing endogenous peroxidase activity, blocking nonspecific back-
ground staining using the Ultra V block, and enhancing the reac-
tion by Primary Antibody Amplifier Quant. The final visualization 
was carried out with diaminobenzidine with additional nuclei 
counterstaining with Modified Mayer’s Hematoxylin (Thermo 
Fisher Scientific).
To exclude influences of tumor histogenesis on the immuno-
phenotype of cancer cells, the presence of serous adenocarcinoma 
of the FT (SAcFT) was a criterion for inclusion in the studied 
group to investigate its molecular-biological markers. All other 
types (mucinous, squamous, etc.) of PCFT were excluded. While 
there were few excluded cases, they may have influenced the 
obtained results. The antibody panel specified in Table 1 was used 
for this research (Thermo Fisher Scientific).
Obtained specimens were examined using a microscope with 
digital camera Zeiss AxioCam ERs 5s and ZEN 2 (blue edition) 
software (Zeiss, Jena, Germany).
Data processing was carried out using Microsoft Excel 2010 
with the application Attestat 12.0.5. Estimation of probable dif-
ferences between comparable indicators was carried out using the 
Student’s t-test. Detection and evaluation of the links between 
indicators was carried out using the nonparametric Spearman 
correlation coefficient (r). A p-value of 0.05 and 95% confidence 
interval was considered statistically significant.
RESULTS
Archive data from the Sumy Regional Pathology Clinical 
Center and Sumy Regional Clinical Oncology Center indicated 
Table 1. Antibody panel used for immunohistochemical research
Antibody Immunized animal Clone Dilution Pattern Evaluation features
ER Rabbit SP1 1:200 Nucleus According to the recommendations of D.C. Allred and taking into account 
the proportion of colored nuclei and the intensity of their stainingPR Rabbit YR85 1:150 Nucleus
HER2/neu Rabbit SP3 1:100 Membrane In points (from 0 to 3), according to the manufacturer’s recommendations 
and taking into account the completeness and intensity of membrane 
staining
Ki-67 Rabbit SP6 1:100 Nucleus 0 point: negative reaction
1 point: weakly positive reaction (n = 0%–30%)
2 points: moderately positive reaction (30% < n < 60%)
3 points: strong positive reaction (n > 60%)
p53 Mouse SP5 1:100 Nucleus Weak reaction (10–25% of positively stained tumor cells), moderate positive 
reaction (25%–50%) and strong positive reaction (>  50%)
Bcl-2 Mouse 100/D5 1:100 Cytoplasm Weak expression (1+): weak cytoplasmic staining of more than 10% of 
tumor cells
Moderate (2+): staining of average intensity more than 10%
Strong (3+): intense staining of more than 10% of tumor cells
VEGF Rabbit Polyclon 1:200 Cytoplasm and 
membrane
0 points: absence of cytoplasmic expression
1 point: weak cytoplasmic staining less than 10% of cells
2 points: weak or moderate expression in 10%–50% of cells
3 points: strong or moderate expression in more than 50% of cells
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; VEGF, vascular endothelial growth factor.
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that PCFT accounted for 1.13% of malignant neoplasms of the 
female reproductive system and 4.36% of malignant neoplasms 
of the uterine appendages (peak incidence was between 50 and 
69 years). FT carcinomas were predominantly localized on one 
side, and bilateral involvement of tubes was detected in only 
16.9% of cases. The tumor process involved the ampulla seg-
ment more often (87.3%) than the isthmus (7.1%) or infundib-
ulum (5.6%). In most cases, FT neoplasias (60.6%) were identi-
fied at stages I–II (Table 2).
Neoplastic spread outside the FT was found in 66.2% of wom-
en during diagnosis. Metastatic tumor dissemination into the 
omentum, peritoneum, ovaries, and regional lymph nodes did 
not depend on the size of the primary focus in the FT. Never-
theless, metastases in iliac and lumbar lymph nodes were detected 
in 26.8% of cases.
Our histologic study showed that the overwhelming majority 
of malignant neoplasms of the FT were SAcFT (93.0% of cases) 
(Fig. 1). Mucinous (2.8%), clear cell (2.8%), and squamous cell 
carcinomas (1.4%) were quite rare.
A total of 88.4% of SAcFT cases showed a high degree of malig-
nancy (low [G3] and moderately differentiated [G2]). Their me-
tastases were more often present in regional lymph nodes (28.2%), 
omentum, peritoneum (11.3%), and ovaries (5.6%).
Immunohistochemical study showed variable expression of 
ER and PR (Fig. 2A, B): ER+PR+, 62.1%; ER+PR–, 21.2%. 
Strong expression of ER and PR in SAcFT correlated with well-
differentiated tumors (low grade cancer) and initial clinical stages 
of disease (p < .001). The presence of metastases in lymph nodes 
was accompanied by significantly lower expression of ER (p < 
.001) and PR (p < .001) in cancer cells compared to cases with-
out metastases (p < .05).
Human epidermal growth factor receptor (HER2)/neu over-
expression was not typical for SAcFT (80.9% of tumors were 
receptor-negative). Nevertheless, most neoplastic FT cells (55.0 ± 
12.2%) expressed Ki-67 receptors (Fig. 2C, D). Table 3 shows 
the division of patients by Ki-67 expression level.
Tumor cell proliferation was characterized by an inverse rela-
tionship with steroid hormone expression (p < .05). In groups 
with positive receptor status (ER+PR+), Ki-67 overexpression 
(more than 60%) was detected in only 46.3% of cases. Conversely, 
tumors with completely negative ER and PR or with only ER 
positivity had significantly higher proliferative activity (63.4% 
and 71.4%, respectively). There were no differences in Ki-67 ex-
pression, clinical tumor stage, or degree of differentiation (p > .05).
In 13 cases (19.7%), a negative reaction was detected for the 
pro-apoptotic protein p53 (Fig. 2F). Fifty-three cases of SAcFT 
(80.3%) were p53-positive. Among them, nine cases (13.6%) 
were weakly positive, 13 cases (19.7%) were moderately posi-
Table 2. Division of PCFT cases according to FIGO classification
Stage No. of patients with PCFT (%)
0 -
I 24 (33.8)
IA–T1aN0M0 5 (7.0)
IB–T1bN0M0 8 (11.3)
IC–11cN0M0 11 (15.5)
II 19 (26.8)
IIA–T2aN0M0 10 (14.1)
IIB–T2bN0M0 3 (4.2)
IIC–T2cN0M0 6 (8.5)
III 28 (39.4)
IIIA–T3aN0 M0 2 (2.8)
IIIB–T3bN0 M0 5 (7.0)
IIIC–T3c N0M0 2 (2.8)
IIIC–T1-3N1M0 19 (26.8)
IV–T1-3N0-1M1 -
Total 71 (100)
PCFT, primary cancer of the fallopian tubes; FIGO, International Federation 
of Gynecology and Obstetrics.
Fig. 1. Serous adenocarcinoma of the fallopian tube. (A) G1 (low degree of malignancy). (B) G2 (high degree of malignancy). (C) G3 (high de-
gree of malignancy). 
A B C
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Fig. 2. Serous adenocarcinoma of the fallopian tube. Immunohistochemical study of estrogen receptors (A, B), Ki-67 (C, D), p53 (E, F), and 
vascular endothelial growth factor (G, H) expression.
A
C
E
G
B
D
F
H
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tive, and 31 cases (47%) were strongly positive (Fig. 2E). The 
presence of these receptors in tumor tissue was found in patients 
of all clinical stages. Strong correlations were identified between 
the presence of p53 and clinical stage (r = 0.77, p < .001), as 
well as between p53 and degree of differentiation (r = 0.58, p < 
.001) (Table 4). Significantly higher p53 expression was identi-
fied in the group of patients with metastases (80.6% ± 2.7%) 
compared to those without metastases (29.7% ± 3.6%).
A total of 81.8% of SAcFT cases were Bcl-2–positive. Most 
of them (96.3%) also had ER and PR (71.4%) expression. Posi-
tive correlations were identified between Bcl-2 and expression 
of ER (r = 0.84, p < .001) and PR (r = 0.69, p < .001). In contrast 
to p53, a moderate negative correlation was identified between 
Bcl-2 and clinical disease stage (r = –0.44, p < .001), as well as be-
tween Bcl-2 and degree of anaplasia (r = –0.52, p < .001). SAcFT 
metastases were associated with decreased anti-apoptotic pro-
tein expression (r = –0.39, p < .01) (Table 5).
The correlation between Ki-67 and p53 expression (p < .05) 
has been established. Patients with high p53 expression (58.3% 
of cases) were predominant in the high Ki-67 expression group. 
There was a negative correlation between expression of Ki-67 
and Bcl-2 (p < .05).
Cytoplasmic expression of VEGF was detected in both tumor 
cells and vascular endothelium. Most patients had moderate or 
strong cytoplasmic signals in endothelial cells (87.9%) and in 
more than 70% of tumor cells located diffusely in all fields of 
view (Fig. 2G, H). Only six cases (9.1%) had weak and moder-
ate focal expression of 10%–50%. Focal weak cytoplasmic reac-
tion, which was present in less than 10% of tumor cells and in 
the endothelium of single vessels, was observed in only two cases 
(3%).
The angiogenic potential of PCFT depends on the degree of 
differentiation (p < .05) and clinical disease stage (p < .05). More-
over, all cases of regional lymph node metastases were accompa-
nied by strong VEGF expression. This result may confirm that 
metastasis of PCFT depends on angiogenesis. In general, steroid-
negative FT tumors were characterized by a higher level of VEGF 
expression. There was weak correlation between expression of 
VEGF and p53 (r = 0.25, p < .05). There was no significant corre-
lation between VEGF expression and the presence of Ki-67 and 
Bcl-2 receptors (p > .05).
DISCUSSION
Numerous scientific publications on PCFT include single obser-
vations of this disease.15,16 Patients with malignant FT neoplasms 
are typically older, which may be due to increased amount of secre-
tory cells in older women.17,18 Morphologically, malignant epi-
thelial tumors of the FT can be comprised of carcinomas of all cell 
types. In our research, the overwhelming majority of malignant 
neoplasms were SAcFT, which demonstrate a high degree of 
malignancy and very aggressive behavior.
The presence of steroid hormone receptors in FT tumors is a 
Table 3. Division of female patients by level of Ki-67 expression in 
SAcFT tissue
Average index of proliferation (%) No. of female patients with SAcFT (%)
0 0
0–30 12 (18.2)
30–60 18 (27.3)
> 60 36 (54.5)
SAcFT, serous adenocarcinoma of the fallopian tubes.
Table 4. Results of p53 expression study in SAcFT depending on 
prevalence, presence of lymphogenous metastases, and degree of 
malignancy
Evaluation’s criteria Average No. of p53 (%)
Disease stage according to FIGO classification
I 10.5 ± 2.2
II 46.8 ± 5.2
III 71.7 ± 3.9
Presence of lesion in regional lymph nodes
N0 29.7 ± 3.6
N1 80.6 ± 2.7
Degree of tumor differentiation
G1 5.6 ± 2.4
G2 35.6 ± 6.2
G3 62.2 ± 4.2
SAcFT, serous adenocarcinoma of the fallopian tubes; FIGO, International 
Federation of Gynecology and Obstetrics.
Table 5. Results of Bcl-2 expression study in SAcFT depending on 
prevalence, presence of lymphogenous metastases, and degree of 
malignancy
Evaluation’s criteria
No. of Bcl-2–positive tumor cases
0 1+ 2+ 3+
Disease stage according to FIGO classification
I (n = 23) - 1 4 18
II (n = 16) 3 2 5 6
III (n = 27) 8 4 9 6
The presence of lesion in regional lymph nodes
N0 (n = 47) 2 5 12 28
N1 (n = 19) 9 2 6 2
Degree of tumor differentiation
G1 (n = 10) - - - 100
G2 (n = 23) 3 - 5 15
G3 (n = 33) 8 7 13 5
SAcFT, serous adenocarcinoma of the fallopian tubes; FIGO, International 
Federation of Gynecology and Obstetrics.
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substantial indicator for the use of hormonal therapy.19 Conversely, 
steroid-negative tumors are contraindicated for hormone therapy. 
The medical literature includes sporadic reports on the use of 
hormonal therapy combined with cytostatics for treatment of 
FT neoplasia.20-22 Increased anaplasia and significant tumor 
spread are associated with decreased steroid-positive cells and an 
increased proportion of steroid-negative FT neoplasms. This can 
be explained by functional and phenotypic simplification of tumor 
cells with decreased ER and PR expression associated with tumor 
progression (increased tumor autonomy degree). Moreover, neo-
plasias with lymph node metastases expressed significantly less 
ER and PR than cases without lymph node metastases (p < .001). 
Our results demonstrate that the presence of steroid hormone 
receptors in SAcFT is an important prognostic biologic charac-
teristic of these neoplasias. Reduced or lost expression of both 
ER and PR in FT tumors is associated with invasion, metastasis, 
and an adverse disease course.
The results of our research indicate that overexpression of HER2/
neu is not typical for PCFT. In contrast to our data, overexpres-
sion of HER2/neu in neoplastic FT tissue has been demonstrated 
by some authors in 25.6%,23 31%,24 and even 89%25 of SAcFT. 
According to our results, we cannot recommend testing for this 
oncoprotein as a prognostic biomarker.
Immunohistochemistry demonstrated a mean Ki-67 of 55.0% ± 
12.2%. Most FT tumors have a proliferation index of more than 
60% (54.5%). PCFT has high proliferative activity, indicating an 
extremely aggressive disease course. In the presence of metastases, 
the level of Ki-67 expression can be considered an independent 
prognostic marker for N-status in PCFT. This contributes to the 
allocation of certain women to the high-risk patient group.
The received data suggests that there is no direct dependency 
between a cell’s steroid status and its ability to divide. This indi-
cates that complex hormonal mechanisms contribute to prolif-
eration. The significant increase in proliferative activity of PR cells 
may demonstrate the significant effect of progesterone on the 
ability of cells to divide.
In our study, 80.3% of SAcFT cases were p53-positive. p53 
mutations were associated with tumor spread. In contrast to 
p53, 72.4% of cases expressed the anti-apoptotic Bcl-2 protein in 
the first stages of the neoplastic process. Blockage of apoptosis 
likely occurs in one of two tumor growth stages via different 
mechanisms; in the early stages, Bcl-2 is activated, while in the 
late stages, mutations in the TP53 gene occur. This results in the 
loss of functional qualities of the protein that it encodes. Exuber-
ant amounts of mutant p53 and decreased wild-type p53 lead 
to suppression of the apoptosis blockade, which consequently 
DNA damage
↑ Bcl-2
↑ Mt p53
↑ Ki-67
Cell cycle 
damage
Tumor’s 
origin
Tumor’s 
progression
p53 gene’s 
mutation
Mt p53 
origin
Blocking of 
apoptosis
Fig. 3. Scheme mutant (mt) of p53 participation in carcinogenesis of primary cancer of the fallopian tubes. DNA damage and appearance of 
mt p53 proteins results in suppression of blocked apoptosis. Conversely, it also stimulates increased antiapoptotic Bcl-2 proteins, which en-
hance the inhibitory effect on apoptosis. This is manifested in altered cell cycle regulation. All of these events lead to increased proliferative 
tumor activity and progression of malignancy.
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increases cell proliferation. Cell division becomes uncontrolled 
and the malignant process actively progresses (Fig. 3).
The p53+ status of SAcFT correlates with a high degree of 
malignancy, significant tumor spread, metastases, and high pro-
liferation. In other words, p53+ status can act as an independent 
prognostic factor for PCFT. In addition, our studies show that the 
Bcl-2+ status of FT tumors correlates with positivity of steroid 
hormone receptors, low degree of anaplasia, and low prolifera-
tion. Bcl-2 overexpression indicates more intense inhibition of 
apoptosis and should be accompanied by more aggressive tumor 
behavior. Nonetheless, according to our obtained data, Bcl-2 
overexpression is a positive predictor for PCFT. This is likely due 
to a combination of Bcl-2 and steroid hormone receptor expres-
sion since the Bcl-2 gene is estrogen-dependent.26,27
FT tumors are characterized by robust angiogenesis. Some-
times, tumor cells can stimulate angiogenesis (angiogenetic 
activation) by forming and releasing angiogenetic factors (e.g., 
VEGFs) that stimulate endothelial cell proliferation and capil-
lary growth.28,29 In our research, the majority of patients (87.9%) 
had moderate or strong VEGF cytoplasmic expression in endo-
thelial cells and in more than 70% of tumor cells were located 
diffusely in all fields of view. Accordingly, constant and intense 
angiogenesis in PCFT determines their fast growth and has adverse 
prognostic implications. We have also detected that the angio-
genic potential of malignant FT tumors correlates with the degree 
of differentiation, clinical disease stage, negative ER/PR status, 
and p53-positive status (p < .05). All cases of metastasis in regional 
lymph nodes were accompanied by strong VEGF expression.
The results of our complex morphological study of PCFT dem-
onstrate factors that should be considered when determining the 
strategy for treating patients with malignant FT tumors, includ-
ing use of antihormonal therapy in cases of steroid positive tumors, 
adjuvant chemotherapy in cases with proapoptotic protein values, 
p53 higher than 10%, proliferative activity more than 60%, and 
use of anti-VEGF therapy in cases with high angiogenic potential. 
Our study was limited by a lack of data on patient lifestyle, which 
may be important, as it is in neoplastic processes in other female 
reproductive organs.30,31
In most cases, PCFT is serous adenocarcinoma. Neoplastic 
cells have high rates of expression for estrogen receptors (83.3%), 
progesterone receptors (62.1%), Ki-67 (55.0% ± 12.2%), p53 
(80.3%), Bcl-2 (81.8%), and VEGF (87.9%), which influence 
tumor aggressiveness. The use of complex morphologic (histo-
logical and immunohistochemical) study of postoperative material 
allows assessment of the degree of malignancy and tumor spread. 
This allows selection of appropriate therapeutic tactics for each 
individual case.
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